Related Experiment Video

Updated: May 23, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Triple-negative breast cancer: an update on neoadjuvant clinical trials

Keith D Amos1, Barbara Adamo, Carey K Anders

  • 1Division of Surgical Oncology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

International Journal of Breast Cancer
|March 31, 2012
PubMed

Insights

Triple-negative breast cancer (TNBC) is aggressive, necessitating new treatments. This review examines neoadjuvant clinical trials for TNBC, focusing on improving patient survival through pathologic complete response.

Area of Science:

  • Oncology
  • Translational Research

Background:

  • Triple-negative breast cancer (TNBC) presents an aggressive clinical challenge with limited therapeutic options.
  • Despite initial chemotherapy response, TNBC often has a poor prognosis, underscoring the urgent need for innovative treatment strategies.
  • The neoadjuvant setting offers a unique platform for evaluating novel therapies for TNBC.

Purpose of the Study:

  • To review current data from completed and ongoing neoadjuvant clinical trials for triple-negative breast cancer.
  • To assess the efficacy of emerging treatment strategies in the neoadjuvant setting for TNBC.
  • To highlight the role of pathologic complete response as a surrogate endpoint for survival in TNBC neoadjuvant trials.

Main Methods:

  • Systematic review of completed and ongoing neoadjuvant clinical trials for TNBC.
  • Analysis of data focusing on treatment response and pathologic complete response rates.
  • Evaluation of the neoadjuvant setting as a model for rapid therapeutic assessment.

Main Results:

  • Neoadjuvant therapies are being actively investigated in numerous clinical trials for TNBC.
  • Pathologic complete response serves as a validated surrogate endpoint in the neoadjuvant setting.
  • Ongoing trials aim to identify more effective treatment strategies to improve survival outcomes for TNBC patients.

Conclusions:

  • The neoadjuvant setting is crucial for accelerating the development of novel therapies for TNBC.
  • Improving pathologic complete response rates in neoadjuvant trials is key to reducing TNBC mortality.
  • Continued research and clinical trial participation are essential for advancing TNBC treatment.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...